Obesity, and Culinary medicine doc. Trying to make the world healthier via weight management, habit change and food. Tweets are my own. IG: @dishanarangmd
Chicago, IL
Joined March 2013
- Tweets961
- Following962
- Followers912
- Likes4.8K
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
💡Can people with obesity reach a “normal” weight through diet & lifestyle alone?
A massive UK study of 177,000+ adults says… not easily.
📉 Over 9 years (no surgery involved):
For those with class 1 obesity (BMI 30–34.9):
🔹Men: 1 in 210 reached normal weight
🔹Women: 1 in 124
For severe obesity (BMI 40–44.9):
🔹Men: 1 in 1290
🔹Women: 1 in 677
⚖️ A 5% weight loss was more common (1 in 7–8/year) — but most regained it within 2–5 years.
🧠 Takeaway:
Community-based weight loss efforts often aren’t enough. We need better tools, access to effective treatments (meds & surgery), and bold public health action.
Source: pmc.ncbi.nlm.nih.gov/article… #ObesityResearch #WeightLossJourney #PublicHealth
Adapted from @NeilFlochMD
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
New research confirms the incredible weight management potential, cardiometabolic benefits, and safety of tirzepatide. Future incretins need to attempt a similar imbalanced agonism of GLP1/GIP. This gets me excited for SURPASS-CVOT & SURMOUNT-MMO!
onlinelibrary.wiley.com/doi/…
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Thank you @EliLillyandCo for innovation on care delivery by providing access to the vial program. Now at a lower price (would have liked lower but 🙏 for a future of lower yet) and more dosing options!
investor.lilly.com/news-rele…
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Because of conventional medicine
-Your mother didn't die in childbirth
-You didn't get polio as a kid
-You've never seen smallpox
-Your friend with type 1 diabetes is alive because of of insulin
-You recovered from that infection because of antibiotics
Science saves lives
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Higher Body Mass Index is strongly linked to less sleep.
Data from objective sleep monitoring with wearables from 120K individuals.
Study link: buff.ly/3EKy2VV
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening heart failure and improved health status in patients with #HFpEF and obesity.
nejm.org/doi/full/10.1056/NE…
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
There is a wisdom from the lived experience of patients that is not found in any medical textbook but that they teach to us in practice
“Running, walking, and crawling are all moving forward, just at different speeds”
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
The FLOW trial was stopped early due to clear benefits for using semaglutide to reduce progression of kidney disease and cardiovascular death in people with #T2D at risk for progressive diabetic kidney disease @US_FDA @novonordiskus
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
There is a move toward revising the definition of obesity away from BMI and more toward better measurements of excess fat, based on this week's Lancet Commission.
We can evaluate someone's level of excess fat by body through measuring someone's waist circumference or waist-to-height ratio.
How does one appropriately measure waist circumference or waist-to-height ratio? 🤔
Check out a video by the NHS from the UK on how to properly make this measurements:
buff.ly/2sywo1x
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Obesity can be under or over-diagnosed when BMI alone as a criteria is used.
Instead, measuring for excess body fat and evaluating for obesity-related diseases is a more accurate method of diagnosing obesity.
See the new Definition and Diagnostic Criteria of Clinical Obesity commission statement, published in Lancet today: buff.ly/42ftb9g
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Woohoo! Medicare has approved Zepbound for the treatment of sleep apnea (OSA)! THIS IS HUGE! Hopefully commercial insurances will soon follow.
Let this be a reminder to people that GLP-1 medications are not just “weight loss” meds. They are cardiometabolic medications with more & more data demonstrating significant improvement in multiple health outcomes.
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Both GLP1-RA and SGLT2 inhibitors reduce cardiovascular events in people with Type 2 Diabetes.
But does combination GLP1-RA + SGLT2 inhibitors reduce CV events more than GLP1-RA alone?
Yes, according to a recent meta-analysis.
In adults with type 2 diabetes, those adding empagliflozin to GLP1-RA had lower risks of MI, stroke, HHF, and all-cause mortality compared to those adding SU to GLP1-RA.
MACE reduction HR 0.75
Heart Failure hospitalizations HR 0.54
buff.ly/3W54atg
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Label expansion as @US_FDA approves the GIP-GLP-1 medicine tirzepatide for moderate to severe obstructive sleep apnea investor.lilly.com/news-rele… $LLY @EliLillyandCo
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
The unique thing about GLP1RAs is that these drugs are not going away despite whatever hysteria is drummed up by skeptics . Unlike most drugs (eg, statins), people desperately want them, not because they will reduce the risk of serious chronic disease (they will)
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
🚫 Why is aspirin 💊 not recommended for primary prevention in Type 2 diabetes?
15,480 adults with T2DM were randomized to aspirin 100mg had significantly lower rates of cardiovascular events 🫀 by 12% vs those on placebo.
Why don't we give aspirin to everyone with T2DM? 🤔
Because aspirin also significantly increased major bleeding events🩸.
So benefits did not outweigh the risks ⚖️
A more personalized approach is possible if we can better identify those with increased platelet activity.
NEJM Ascend trial: buff.ly/2BOfh3h
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Semaglutide is an option for treating obesity in patients with kidney failure on dialysis. This could significantly aid in their weight loss efforts and improve their chances of being listed for kidney transplantation. #semaglutide
dom-pubs.pericles-prod.liter…
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Breaking: Lilly’s Zepbound® (tirzepatide) outperforms Wegovy® (semaglutide) in weight loss trial over 72 weeks
🚨 SURMOUNT-5 Top-line results:
🔹 Zepbound: 20.2% avg. weight loss (50.3 lbs)
Vs.
🔹 Wegovy: 13.7% avg. weight loss (33.1 lbs)
Zepbound, a dual GIP/GLP-1 agonist, delivered 47% greater weight loss than Wegovy, a mono GLP-1 agonist, in adults with obesity (no diabetes).
#ObesityMedicine #Tirzepatide #ClinicalTrials
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM retweeted
Obesity management medications and metabolic bariatric surgery, better together 🤲
"Rather than viewing these highly effective and complementary treatment approaches as inevitable competitors, learning in whom, when, and how to combine them could be even more valuable and relevant to patient care."
First guidelines on the use of medications and metabolic surgery, along with a systematic review and editorial academic.oup.com/bjs/article…. academic.oup.com/bjs/article… academic.oup.com/bjs/article…
